Clinical Trial IDNCT04304781
Lead SponsorDanielle Kim Turgeon
Principal Investigator
Start Date2020-06-01
Completion Date2022-06-01
Study TypeInterventional
PhasePhase 1
StatusNot yet recruiting

Purpose

The overall aim of this feasibility study is to develop new technologies for improved detection of cholangiocarcinoma using the SFE-based molecular-imaging mini-cholangioscope (MC) system. This study will combine the use of a fluorescent-labeled peptide dimer that binds specifically to know biomarkers of cholangiocarcinoma for use as a novel imaging agent to guide endoscopic biopsies. This Phase 1B study will be used to provide early evidence of efficacy for the topical application of a peptide dimer that binds to molecular targets that are specific for biliary intra-epithelial neoplasia. A dimer is needed because cancer in the biliary tract is genetically heterogeneous. QRH binds specifically to Epidermal Growth Factor Receptor (EGFR), and KSP binds specifically to Human Epithelial Growth Factor Receptor (HER2). The study will look at peptide binding in subjects having a medical condition requiring an ERCP to diagnose a potential biliary disorder. The Phase 1A first-in-human studies of safety with topical administration by ingestion of KSP/QRH dimer (HUM00141420) has been completed.

Conditions

ConditionInterventionPhase
CholangiocarcinomaDrug: KSP/QRH dimerPhase 1

Eligibility

AgeGenderAccepts Healthy Volunteers
18 Years to 100 YearsAllNo